I really don't want to be a doctor

Chapter 191 China Institute of Biopharmaceuticals
As early as the 19s, American surgeon William Coley used Coley toxin to treat tumors, which opened a precedent for tumor immunotherapy.

However, this is a conventional tumor immunotherapy, that is, to improve the anti-tumor effect by regulating the immune function in the human body.

In tumor immunotherapy, there is a brand-new way, that is, immune checkpoint inhibitors.

Checkpoint inhibitors (CPI) can improve the anti-tumor effect by blocking the interaction of inhibitory receptors expressed on T cells and related ligands, and regulating the normal immune cell activity of the body.

In the previous life, this brand-new treatment method opened a new era of tumor treatment, which can be said to be one of the most important discoveries in the history of modern medicine.

For example, as far as lung cancer is concerned, once immune checkpoint inhibitor therapy is effective and lasts for a long time, 20% of lung cancer patients will live beyond 10 years.But living for 10 years is a very remarkable thing for a cancer patient.

Therefore, Jing Xiaoran has absolute certainty that in the near future, tumor immunotherapy will surpass tumor targeted therapy and become the trend of future tumor treatment.

"Mr. Zhu, since I dare to say that, I have my reasons. Then what do you think of immune checkpoint inhibitors?"

Jing Xiaoran smiled softly, he looked at Zhu Xianqing beside him, a trace of curiosity flashed in his eyes.

He knew that Zhu Xianqing's research field was in the direction of tumors, and that Pfizer was also the world's most famous pharmaceutical company, so he was curious, how do these front-end scholars view immune checkpoint inhibitors?

Did they predict the future development of immune checkpoint inhibitors?
Zhu Xianqing groaned, searching for things about immune checkpoint inhibitors in his mind.

His research field is in the direction of targeted tumor therapy, but Zhu Xianqing is quite familiar with immunotherapy.

This is new territory, but new territory is not necessarily true, and immune checkpoint inhibitors have not yet been proven effective.

Judging from the current internal information of Pfizer, immune checkpoint inhibitors are one of the hot drugs in the future, but whether they can surpass targeted drugs in the future can only be verified after the drugs enter clinical trials.

However, Zhu Xianqing knew that within Pfizer, there was a senior figure in the R&D department.

The research and development direction of this big coffee is immune checkpoint inhibitors. He bluntly said that future immune checkpoint inhibitors will definitely change the pattern of tumor treatment.

But those who hold this point of view are in the minority after all.

Zhu Xianqing thought for a while and said: "My research and development direction at Pfizer is tumors, so according to what I have learned so far, immunotherapy will set off a wave of research and development in the future, but whether it can surpass targeted therapy drugs, I dare not affim."

What Zhu Xianqing didn't realize was that the way he talked with Jing Xiaoran was more and more like getting along with a peer.

But the age gap between them is nearly 20 years!
"I see." Jing Xiaoran smiled, "Mr. Zhu, let's wait and see."

Zhu Xianqing looked at Jing Xiaoran who was full of confidence, and really didn't know where his confidence came from.

"Student Jing, it looks like you know a lot about immune checkpoint inhibitors, can you tell me where you are now?"

Zhu Xianqing hesitated for a moment, and finally asked this question.

Which step he refers to, of course, refers to the research on immune checkpoint inhibitors.

Since Jing Xiaoran admires immune checkpoint inhibitors so much, it means that he is definitely not researching in the form of words, and Jing Xiaoran will also dabble in the basic research of drugs.

Jing Xiaoran pursed his lips and smiled, and said softly: "Mr. Zhu, do you mean that you are going to join our laboratory?"

The progress of laboratory projects is generally not informed to others at will, unless it is an internal personnel, and it must also be an internal research and development personnel who signed a non-disclosure agreement.

Zhu Xianqing looked a little embarrassed. He is still a member of Pfizer, so he was a little negligent in this regard.

"I'm sorry, I'm just curious, I don't mean to inquire about the news."

Jing Xiaoran smiled and said: "It's okay, if Mr. Zhu is very interested, I do have some research and development information on immune checkpoint inhibitors here, which I can share with you."

"Yes, but I haven't planned to say that I want to join your laboratory?"

Zhu Xianqing was stunned for a moment, and looked at Jing Xiaoran in some puzzlement.

"It's okay. This is just a small part of the research and development progress of the experiment, and it's not top-secret content." Jing Xiaoran smiled, "The most important thing is that I believe in your character, Mr. Zhu."

After listening to Jing Xiaoran's words, Zhu Xianqing was not only slightly moved by trust, but also came to a conclusion that Jing Xiaoran's current research and development progress on immune checkpoint inhibitors may be more than imagined.

"Thank you." Zhu Xianqing smiled at Jing Xiaoran.

This seemingly ordinary and ordinary boy seems to have a strange charm, which makes people feel very comfortable.

"arrive."

The taxi moved forward smoothly, and stopped in Fancheng Optics Valley Industrial Zone half an hour later.

"Jing Xiaoran, let me ask you a question."

As soon as he got out of the car, Zhu Xianqing asked suddenly.

"You say."

Jing Xiaoran led the way ahead, and looked back at Zhu Xianqing.

"How many people are there in your current laboratory?" Zhu Xianqing asked.

"Let me think about it." Jing Xiaoran paused, "Including me, there are six people in total."

"Oh." Zhu Xianqing nodded, "That's not bad."

He had heard from Hammer before that there was only Jing Xiaoran, a polished commander, in the laboratory here, but he didn't expect that there were already six of them.

It's just that he didn't know that these people included Wang Tuo and other three seniors, Hong Sheng and Lin Yitian.

Except Lin Yitian, everyone else can be said to be a rookie in the scientific research field, and Lin Yitian is not a scientific research talent, he is a management talent.As for Hong Sheng, he may not even be considered a rookie, it is a blank slate.

When they came to the door of the experiment, Jing Xiaoran and Zhu Xianqing stopped in their tracks.

The plaque at the entrance of the laboratory reads "Fancheng Shenzhou Institute of Biological Medicine".

"It's a good name." Zhu Xianqing smiled, "Shenzhou...it's quite easy to pronounce."

Jing Xiaoran was a little embarrassed. He thought about the name of the laboratory for a long time, but after much deliberation, it was not good at all. In the end, he could only adopt Jin Miao's opinion, and call it the Shenzhou Institute of Biopharmaceuticals.

Shenzhou is filled with a patriotic atmosphere of "Secondary Two", but Jing Xiaoran can barely accept it.

Walking into the lab, there was no one there.

"Is no one here?" Zhu Xianqing asked curiously, "Where are the other five people?"

Today is not a rest day, there is no one in such a large laboratory.

"They are on vacation recently." Jing Xiaoran explained, "I asked them to go home and prepare some materials, so they don't have to come recently."

"En." Zhu Xianqing nodded, not to dwell on this topic.

Jing Xiaoran took Zhu Xianqing to visit various instruments and equipment in the laboratory.

(End of this chapter)